<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006476</url>
  </required_header>
  <id_info>
    <org_study_id>CRC-PHASE I/II-PH1/073</org_study_id>
    <secondary_id>CDR0000068303</secondary_id>
    <secondary_id>NCI-954</secondary_id>
    <nct_id>NCT00006476</nct_id>
  </id_info>
  <brief_title>Suramin in Treating Patients With Recurrent Bladder Cancer</brief_title>
  <official_title>A Phase I Study of Intravesicular Suramin in Recurrent Superficial Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Suramin may stop the growth of bladder cancer by stopping blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of suramin in treating patients who have&#xD;
      recurrent bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of suramin in patients with recurrent&#xD;
           superficial bladder cancer.&#xD;
&#xD;
        -  Confirm that there is no significant systemic absorption of this drug when administered&#xD;
           intravesically in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study.&#xD;
&#xD;
      At approximately 14-18 days after surgical resection of bladder tumor(s), patients receive&#xD;
      intravesicular suramin via urethral catheter installation into the bladder over 2 hours&#xD;
      weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of suramin until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients&#xD;
      develop dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at 2-4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-15 patients will be accrued for this study over 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>suramin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven recurrent superficial bladder cancer&#xD;
&#xD;
               -  Intermediate prognosis as defined by the following:&#xD;
&#xD;
                    -  Recurrent, multiple Ta, T1 carcinoma&#xD;
&#xD;
                    -  Multiple (1-7) tumors&#xD;
&#xD;
                    -  Tumors resected previously must be histological grade G1 or G2 OR&#xD;
&#xD;
          -  Previously treated superficial bladder cancer requiring followup cystoscopy&#xD;
&#xD;
               -  Recurrent disease diagnosed at surgery&#xD;
&#xD;
          -  No tumor invasion into muscle or carcinoma in situ&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,500/mm3&#xD;
&#xD;
          -  Platelet count at least 150,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No clinically significant hepatic disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
&#xD;
          -  No history of adrenal insufficiency&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated cone-biopsied&#xD;
             carcinoma in situ of the cervix or nonmelanoma skin cancer&#xD;
&#xD;
          -  No history of difficult catheterization&#xD;
&#xD;
          -  No confusion or disorientation&#xD;
&#xD;
          -  No other condition that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to the bladder&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior major thoracic or abdominal surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from prior therapy and stable for 4 weeks&#xD;
&#xD;
          -  At least 6 weeks since prior intravesicular therapy&#xD;
&#xD;
          -  No prior or concurrent investigational drugs&#xD;
&#xD;
          -  No concurrent anticoagulants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian L. Harris, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Oxford University Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Ord JJ, Streeter E, Jones A, Le Monnier K, Cranston D, Crew J, Joel SP, Rogers MA, Banks RE, Roberts IS, Harris AL. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma. Br J Cancer. 2005 Jun 20;92(12):2140-7. doi: 10.1038/sj.bjc.6602650.</citation>
    <PMID>15928663</PMID>
  </results_reference>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>November 6, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>stage 0 bladder cancer</keyword>
  <keyword>stage I bladder cancer</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suramin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

